Ross Upton
@drrossupton.bsky.social
Founder CEO & Chief Scientific Officer, Ultromics
AI, Echocardiography, #CardioSky
University of Oxford
AI, Echocardiography, #CardioSky
University of Oxford
Reposted by Ross Upton
Transthyretin amyloid cardiomyopathy #ATTR:
A paradigm for advancing precision medicine
#CardioSky
academic.oup.com/eurheartj/ar...
@escardio.bsky.social @jimjanuzzi.bsky.social @hvanspall.bsky.social @anastasiasmihaili.bsky.social @load-dependent.bsky.social @victoriadelgadomd.bsky.social
A paradigm for advancing precision medicine
#CardioSky
academic.oup.com/eurheartj/ar...
@escardio.bsky.social @jimjanuzzi.bsky.social @hvanspall.bsky.social @anastasiasmihaili.bsky.social @load-dependent.bsky.social @victoriadelgadomd.bsky.social
March 17, 2025 at 1:15 PM
Transthyretin amyloid cardiomyopathy #ATTR:
A paradigm for advancing precision medicine
#CardioSky
academic.oup.com/eurheartj/ar...
@escardio.bsky.social @jimjanuzzi.bsky.social @hvanspall.bsky.social @anastasiasmihaili.bsky.social @load-dependent.bsky.social @victoriadelgadomd.bsky.social
A paradigm for advancing precision medicine
#CardioSky
academic.oup.com/eurheartj/ar...
@escardio.bsky.social @jimjanuzzi.bsky.social @hvanspall.bsky.social @anastasiasmihaili.bsky.social @load-dependent.bsky.social @victoriadelgadomd.bsky.social
🚀 Transthyretin Amyloid Cardiomyopathy: A Paradigm for Advancing Precision Medicine 🚀
📖 Read the full article: doi.org/10.1093/eurh...
#Cardiology #PrecisionMedicine #Amyloidosis #ATTRCM @escardio.bsky.social
📖 Read the full article: doi.org/10.1093/eurh...
#Cardiology #PrecisionMedicine #Amyloidosis #ATTRCM @escardio.bsky.social
Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine
Abstract. Development of specific therapies addressing the underlying diseases’ mechanisms constitutes the basis of precision medicine. Transthyretin cardi
doi.org
March 18, 2025 at 10:36 AM
🚀 Transthyretin Amyloid Cardiomyopathy: A Paradigm for Advancing Precision Medicine 🚀
📖 Read the full article: doi.org/10.1093/eurh...
#Cardiology #PrecisionMedicine #Amyloidosis #ATTRCM @escardio.bsky.social
📖 Read the full article: doi.org/10.1093/eurh...
#Cardiology #PrecisionMedicine #Amyloidosis #ATTRCM @escardio.bsky.social
Reposted by Ross Upton
Does tafamidis treatment associate w/ increased survival in octogenarians pts w/ wild-type amyloid transthyretin cardiomyopathy? Carlos Aguiar discusses recent real-world data on Cardiology This Week Summary #ESCTVToday bit.ly/4iW9S9I
Sign up for reminders so you Never Miss a Beat bit.ly/4eqyaac
Sign up for reminders so you Never Miss a Beat bit.ly/4eqyaac
March 18, 2025 at 10:18 AM
Does tafamidis treatment associate w/ increased survival in octogenarians pts w/ wild-type amyloid transthyretin cardiomyopathy? Carlos Aguiar discusses recent real-world data on Cardiology This Week Summary #ESCTVToday bit.ly/4iW9S9I
Sign up for reminders so you Never Miss a Beat bit.ly/4eqyaac
Sign up for reminders so you Never Miss a Beat bit.ly/4eqyaac
Reposted by Ross Upton
🧠 Can Imaging Be a Surrogate Endpoint in Amyloidosis Trials?
A recent JACC:CVI review by Dorbala et al. highlights the role of imaging biomarkers in clinical trials for amyloidosis.
www.jacc.org/doi/abs/10.1...
A recent JACC:CVI review by Dorbala et al. highlights the role of imaging biomarkers in clinical trials for amyloidosis.
www.jacc.org/doi/abs/10.1...
March 10, 2025 at 4:38 PM
🧠 Can Imaging Be a Surrogate Endpoint in Amyloidosis Trials?
A recent JACC:CVI review by Dorbala et al. highlights the role of imaging biomarkers in clinical trials for amyloidosis.
www.jacc.org/doi/abs/10.1...
A recent JACC:CVI review by Dorbala et al. highlights the role of imaging biomarkers in clinical trials for amyloidosis.
www.jacc.org/doi/abs/10.1...
🧠 Can Imaging Be a Surrogate Endpoint in Amyloidosis Trials?
A recent JACC:CVI review by Dorbala et al. highlights the role of imaging biomarkers in clinical trials for amyloidosis.
www.jacc.org/doi/abs/10.1...
A recent JACC:CVI review by Dorbala et al. highlights the role of imaging biomarkers in clinical trials for amyloidosis.
www.jacc.org/doi/abs/10.1...
March 10, 2025 at 4:38 PM
🧠 Can Imaging Be a Surrogate Endpoint in Amyloidosis Trials?
A recent JACC:CVI review by Dorbala et al. highlights the role of imaging biomarkers in clinical trials for amyloidosis.
www.jacc.org/doi/abs/10.1...
A recent JACC:CVI review by Dorbala et al. highlights the role of imaging biomarkers in clinical trials for amyloidosis.
www.jacc.org/doi/abs/10.1...